Omalizumab may protect allergic patients against COVID-19: A systematic review

Omalizumab, which downregulates the immunoglobulin E (IgE) receptor site on plasmacytoid dendritic cells and thereby increases interferon-α (INF-α) production, may shorten the duration of viral infections by enhancing the antiviral immunity. A systematic review was conducted to investigate whether p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghiglioni, Daniele Giovanni, Cozzi, ET Laura, Castagnoli, Riccardo, Bruschi, Gaia, Maffeis, Laura, Marchisio, Paola Giovanna, Marseglia, Gian Luigi, Licari, Amelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826982/
https://www.ncbi.nlm.nih.gov/pubmed/36644451
http://dx.doi.org/10.1016/j.waojou.2023.100741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826982/
https://www.ncbi.nlm.nih.gov/pubmed/36644451
http://dx.doi.org/10.1016/j.waojou.2023.100741

Ejemplares similares